NON-HODGKIN LYMPHOMA

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aim…

This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…

This study tested an experimental drug called IPH6501 in 23 people with a type of blood cancer called Non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The main goals were to check the drug's safety and find the best dose. The trial was stopped ear…

This study tested whether the blood pressure drug telmisartan could prevent acute graft-versus-host disease (GVHD) in 32 people with blood cancers receiving a stem cell transplant. GVHD is a serious complication where donor cells attack the patient's body. The trial was stopped e…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This early-stage trial tested a two-step radiation treatment for people with non-Hodgkin lymphoma that had come back or stopped responding to standard therapies. The treatment uses a special protein to deliver radiation directly to cancer cells. Only one person enrolled before th…

This study tested whether a short daily breathing exercise (inspiratory muscle strength training) combined with a personalized exercise plan could improve heart health and fitness in lymphoma survivors. Only one person enrolled before the study was stopped early, so no meaningful…